The company's low P/E is due to its outlook for shrinking earnings. Investors believe the potential for earnings improvement doesn't justify a higher P/E, limiting the chances of a strong share price rise soon.
Quanex Building Products is undervalued, presenting a good opportunity to increase holdings. The company's future outlook isn't fully reflected in the current share price, making it a good time to invest.
The large scale share sell-off from the Independent Lead Director around current prices raises concern. Lack of recent insider purchases despite significant ownership increases caution towards the company.
Gainers: •$Okta(OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo(STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics(TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals(AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
Quanex Building Products股票討論區
專欄Today's Pre-Market Stock Movers: AVGO, RKLB, LULU, XOM and More
In reaction to earnings/guidance:
• $HashiCorp(HCP.US)$ +16.8%,$Lululemon Athletica(LULU.US)$ +9.7%,$PagerDuty(PD.US)$ +5%,$nCino(NCNO.US)$ +3.8% (also Bank Operating System selected by Rabobank Australia and New Zealand),$博通(AVGO.US)$ +2.1%
Other news:
• $Ooma(OOMA.US)$ +3.5% (acquires Junction Networks also reports earnings)
• $Momentus(MNTS.US)$ +3.5% (files for $200 mln mixed securities shelf offering)
• $Humacyte(HUMA.US)$ +2.9% (fi...
Quanex建築產品公司(Quanex Building Products) 是2008年以13美元上市的美國公司,當前價格23.98,14年來平均回報率為4.5%,比較平淡。
5年來毛利率在22%上下波動,淨資產收益率則是從4.8上升到了14.7%,利潤水平在板塊內偏低。
5年來營收前4年變化不大,2021年大幅增長25.9%,營業利潤則是近三年連續增長,2021年達到46.6%,淨利潤2019年大幅虧損,2020扭虧並連續兩年增長。2019年虧損是由於當年有7,460萬的資本性資產減值。
2022前兩季度營收營業利潤和淨利潤分別增長17.9%,46.4%,68.6%。
2021年利潤表顯示利息費用逐年遞減,2021年僅佔營業利潤的3%,負擔很低。
5年來資產負債率從47.4%下降到41.1%,應收款項和存貨比例都很低,但是2021年累計增長了5130萬,遠超淨利潤增長的1848萬,利潤增長比較虛。
商譽及其他無形資產2.17億,佔淨資產4.2億的52%。長期借款7,571.4萬,比例不算高。
5年來經營淨額大比例超過投資淨額,...
專欄Today's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more
• $Okta(OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
暫無評論